Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus

Table 1 Laboratory findings at baseline, treatments and outcomes of dialysis cases

Parameters	Case 1	Case 2	Case 3	Case 4
Age (yr)	62	61	72	70
Sex	Female	Male	Male	Male
BMI (kg/m2)	17.9	20.9	19.4	22.3
HCV genotype	1b	1b	1b	1b
Cause of dialysis	CGN	CGN	CGN	DM
IFN-based therapy: Outcome	PEG-IFN-α2a: partial response	Naive: NA	Naive: NA	Naive: NA
At the start of therapy
HCV RNA (log10 IU/mL)	4.7	6	6.3	4.9
ALT (IU/L)	54	18	36	19
AST (IU/L)	36	20	31	13
WBC (cells/μL)	1660	3780	4330	5200
Hemoglobin (g/dL)	10.5	11.3	12.4	11.6
Platelets (cells/μL)	72000	204000	146000	218000
RAVs at baseline	D168E, Y93Y/H, Q80L	None	None	None
Severity of liver disease	Chronic hepatitis	Chronic hepatitis	Chronic hepatitis	Chronic hepatitis
Treatment and outcome
Daclatasvir dosage (mg)	60	60	60	60
Asnaprevir dosage (mg)	200	200	200	200
Week of serum HCV RNA disappearance	2	3	3	2
Adherence to daclatasvir	100%1	100%	100%	100%
Adherence to asnaprevir	100%1	100%	100%	100%
Weeks of therapy	9	24	24	24
Response	Breakthrough	SVR12	SVR12	SVR12
Adverse events	None	None	None	Heart failure, Pneumonitis, Myocardial ischemia

¹The patient’s adherence to both drugs was 100% until the date of the discontinuation of the combination therapy. BMI: Body mass index; CGN: Chronic glomerulonephritis; DM: Diabetes mellitus; NA: Not applicable; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; WBC: White blood cells; RAVs: Resistance-associated variants; SVR: Sustained virological response.